Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-4316614 (St ...

Edwards Lifesciences Corporation (EW) reported adjusted earnings per share (EPS) of 64 cents in fourth-quarter 2023, in line with the Zacks Consensus Estimate. The figure is also in line with the year-ago quarter’s level.The quarter’s one-time adjustments primarily include the spin-off of Critical care and the prior period’s ongoing tax.GAAP EPS were 61 cents in the quarter, down 6.2% year over year.For the full year, adjusted earnings were $2.30 per share, down 5.7% from the year-ago period’s levels. It al ...

Edwards Lifesciences Corporation (NYSE:EW) Q4 2023 Earnings Conference Call February 6, 2024 5:00 PM ET Company Participants Mark Wilterding - Investor Relations and Treasurer Bernard Zovighian - Chief Executive Officer Scott Ullem - Chief Financial Officer Daveen Chopra - Global Leader of TMTT Larry Wood - Group President of TAVR and Surgical Structural Heart Wayne Markowitz - Global Leader of Surgical Structural Heart Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Trav ...

For the quarter ended December 2023, Edwards Lifesciences (EW) reported revenue of $1.53 billion, up 13.8% over the same period last year. EPS came in at $0.64, compared to $0.64 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.5 billion, representing a surprise of +2.27%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.64.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...

Edwards Lifesciences (EW) came out with quarterly earnings of $0.64 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.64 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this medical device maker would post earnings of $0.59 per share when it actually produced earnings of $0.59, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Edwards Lifesciences, wh ...

Edwards Lifesciences (EW) recently secured the FDA’s approval for the EVOQUE tricuspid valve replacement system, a first-of-its-kind transcatheter therapy for the treatment of tricuspid regurgitation (TR). The system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.The latest development will strongly boost the company’s Transcatheter Mitral and Tricuspid ...

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Edwards Lifesciences (EW) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart t ...

In its upcoming report, Edwards Lifesciences (EW) is predicted by Wall Street analysts to post quarterly earnings of $0.64 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $1.5 billion, representing a year-over-year increase of 11.1%.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's ea ...

Edwards Lifesciences (EW) shares rallied 6.2% in the last trading session to close at $78.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.2% loss over the past four weeks.Edwards Lifesciences scored a strong price increase, on investors’ optimism surrounding its impending fiscal fourth-quarter 2023 financial results, which is slated to release on Feb 6 post the closing bell. Per the Zacks Consensus Esti ...